Francisco Leyva

List of Publications by Year
in descending order

87 papers	5,331 citations	117571 34 h-index	88593 70 g-index
89 all docs	89 docs citations	89 times ranked	5230 citing authors

#	Article	IF	Citations
1	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2021, 42, 3427-3520.	1.0	899
2	Uric Acid and Survival in Chronic Heart Failure. Circulation, 2003, 107, 1991-1997.	1.6	532
3	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace, 2022, 24, 71-164.	0.7	370
4	Late Gadolinium Enhancement and theÂRisk for Ventricular Arrhythmias or SuddenÂDeath in Dilated Cardiomyopathy. JACC: Heart Failure, 2017, 5, 28-38.	1.9	262
5	Myocardial strain measurement with feature-tracking cardiovascular magnetic resonance: normal values. European Heart Journal Cardiovascular Imaging, 2015, 16, 871-881.	0.5	195
6	Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 29.	1.6	190
7	Left Ventricular Midwall Fibrosis as a Predictor of Mortality and Morbidity After Cardiac Resynchronization Therapy in Patients With Nonischemic Cardiomyopathy. Journal of the American College of Cardiology, 2012, 60, 1659-1667.	1.2	169
8	Late gadolinium enhancement-cardiovascular magnetic resonance as a predictor of response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy. Europace, 2007, 9, 1031-1037.	0.7	155
9	Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation. JACC: Heart Failure, 2013, 1, 500-507.	1.9	147
10	Intraventricular Dyssynchrony Predicts Mortality and Morbidity After Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2007, 50, 243-252.	1.2	138
11	20 Years of Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2014, 64, 1047-1058.	1.2	137
12	Mechanical effects of left ventricular midwall fibrosis in non-ischemic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 1.	1.6	111
13	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. European Journal of Heart Failure, 2020, 22, 2349-2369.	2.9	101
14	Effect of telemonitoring of cardiac implantable electronic devices on healthcare utilization: a metaâ€analysis of randomized controlled trials in patients with heart failure. European Journal of Heart Failure, 2016, 18, 195-204.	2.9	100
15	Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. European Heart Journal, 2013, 34, 1869-1874.	1.0	85
16	Improvement in Cardiac Energetics by Perhexiline in Heart Failure Due to DilatedÂCardiomyopathy. JACC: Heart Failure, 2015, 3, 202-211.	1.9	77
17	Interplay Between Right Ventricular Function and Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2013, 61, 2153-2160.	1.2	74
18	Outcomes of Cardiac Resynchronization Therapy With or Without Defibrillation in Patients With Nonischemic Cardiomyopathy. Journal of the American College of Cardiology, 2017, 70, 1216-1227.	1.2	69

#	Article	IF	Citations
19	Myocardial Infarction Does Not Preclude Electrical and Hemodynamic Benefits of Cardiac Resynchronization Therapy in Dyssynchronous Canine Hearts. Circulation: Arrhythmia and Electrophysiology, 2010, 3, 361-368.	2.1	65
20	Implementation and reimbursement of remote monitoring for cardiac implantable electronic devices in Europe: a survey from the health economics committee of the European Heart Rhythm Association. Europace, 2015, 17, 814-818.	0.7	62
21	What is treatment success in cardiac resynchronization therapy?. Europace, 2009, 11, v58-v65.	0.7	61
22	Myocardial Fibrosis as a Predictor of Sudden Death in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2021, 77, 29-41.	1.2	61
23	Left ventricular reverse remodelling, longâ€term clinical outcome, and mode of death after cardiac resynchronization therapy. European Journal of Heart Failure, 2011, 13, 43-51.	2.9	59
24	Left ventricular lead position, mechanical activation, and myocardial scar in relation to left ventricular reverse remodeling and clinical outcomes after cardiac resynchronization therapy: A feature-tracking and contrast-enhanced cardiovascular magnetic resonance study. Heart Rhythm, 2016, 13, 481-489.	0.3	58
25	Long-term effects of upgrading from right ventricular pacing to cardiac resynchronization therapy in patients with heart failure. Europace, 2008, 11, 495-501.	0.7	57
26	Leadless Pacemaker Implantation inÂHemodialysis Patients. JACC: Clinical Electrophysiology, 2019, 5, 162-170.	1.3	54
27	Incidental cardiac findings on computed tomography imaging of the thorax. BMC Research Notes, 2010, 3, 326.	0.6	50
28	Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. European Heart Journal, 2009, 30, 2749-2757.	1.0	48
29	Long-term requirement for pacemaker implantation after cardiac valve replacement surgery. Heart Rhythm, 2017, 14, 529-534.	0.3	48
30	Cardiac Resynchronization Therapy Using Quadripolar Versus Nonâ€Quadripolar Left Ventricular Leads Programmed to Biventricular Pacing With Singleâ€Site Left Ventricular Pacing: Impact on Survival and Heart Failure Hospitalization. Journal of the American Heart Association, 2017, 6, .	1.6	45
31	Cardiac resynchronisation therapy in patients with heart failure and a normal QRS duration: the RESPOND study. Heart, 2011, 97, 1041-1047.	1.2	43
32	Reference ranges for three-dimensional feature tracking cardiac magnetic resonance: comparison with two-dimensional methodology and relevance of age and gender. International Journal of Cardiovascular Imaging, 2018, 34, 761-775.	0.7	42
33	Validation of a simple risk stratification tool for patients implanted with Cardiac Resynchronization Therapy: the <scp>VALIDâ€CRT</scp> risk score. European Journal of Heart Failure, 2015, 17, 717-724.	2.9	41
34	Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverterâ€defibrillator therapies and hospitalizations. European Journal of Heart Failure, 2018, 20, 1472-1481.	2.9	39
35	Radial dyssynchrony assessed by cardiovascular magnetic resonance in relation to left ventricular function, myocardial scarring and QRS duration in patients with heart failure. Journal of Cardiovascular Magnetic Resonance, 2009, 11, 50.	1.6	34
36	Female Gender is Associated with a Better Outcome after Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 82-88.	0.5	34

#	Article	IF	Citations
37	Out-of-hospital cardiac arrest due to idiopathic ventricular fibrillation in patients with normal electrocardiograms: results from a multicentre long-term registry. Europace, 2019, 21, 1670-1677.	0.7	34
38	Long-term clinical outcomes of cardiac resynchronization therapy with or without defibrillation: impact of the aetiology of cardiomyopathy. Europace, 2018, 20, 1804-1812.	0.7	33
39	Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review. European Heart Journal, 2020, 41, 1976-1986.	1.0	33
40	Cardiac operations and interventions during the COVID-19 pandemic: a nationwide perspective. Europace, 2021, 23, 928-936.	0.7	33
41	Cardiac resynchronization therapy guided by cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2010, 12, 64.	1.6	32
42	Survival after cardiac resynchronization therapy: results from 50Â084 implantations. Europace, 2019, 21, 754-762.	0.7	31
43	Changes in QRS Area and QRS Duration After Cardiac Resynchronization Therapy Predict Cardiac Mortality, Heart Failure Hospitalizations, and Ventricular Arrhythmias. Journal of the American Heart Association, 2019, 8, e013539.	1.6	30
44	Myocardial Fibrosis Predicts Ventricular Arrhythmias and Sudden Death After Cardiac Electronic Device Implantation. Journal of the American College of Cardiology, 2022, 79, 665-678.	1.2	30
45	Feature-tracking cardiovascular magnetic resonance as a novel technique for the assessment of mechanical dyssynchrony. International Journal of Cardiology, 2014, 175, 120-125.	0.8	29
46	Short-Term Hemodynamic Effects of Cardiac Resynchronization Therapy in Patients With Heart Failure, a Narrow QRS Duration, and No Dyssynchrony. Circulation, 2009, 120, 1687-1694.	1.6	28
47	Haemodynamic effects of cardiac resynchronization therapy using single-vein, three-pole, multipoint left ventricular pacing in patients with ischaemic cardiomyopathy and a left ventricular free wall scar: the MAESTRO study. Europace, 2016, 18, 1227-1234.	0.7	25
48	Fluoroscopic Left Ventricular Lead Position and the Longâ€Term Clinical Outcome of Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 785-797.	0.5	24
49	Absolute survival after cardiac resynchronization therapy according to baseline QRS duration: A multinational 10-year experience. American Heart Journal, 2014, 167, 203-209.e1.	1.2	22
50	European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology. Europace, 2022, 24, 165-172.	0.7	20
51	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. Europace, 2021, 23, 1324-1342.	0.7	18
52	Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy. Heart, 2019, 105, 1825-1831.	1.2	15
53	Current and future role of cardiovascular magnetic resonance in cardiac resynchronization therapy. Heart Failure Reviews, 2011, 16, 251-262.	1.7	14
54	National Institute for Health and Care Excellence 2014 guidance on cardiac implantable electronic devices: health economics reloaded. Europace, 2015, 17, 339-342.	0.7	13

#	Article	IF	Citations
55	The Role of Cardiovascular Magnetic Resonance in Cardiac Resynchronization Therapy. Heart Failure Clinics, 2017, 13, 63-77.	1.0	12
56	Longâ€Term Outcomes of Cardiac Resynchronization Therapy Using Apical Versus Nonapical Left Ventricular Pacing. Journal of the American Heart Association, 2018, 7, e008508.	1.6	12
57	Longâ€term outcomes of cardiac resynchronization therapy in adult congenital heart disease. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 573-580.	0.5	12
58	Sexâ€Specific Differences in Survival and Heart Failure HospitalizationÂAfter Cardiac Resynchronization Therapy With or Without Defibrillation. Journal of the American Heart Association, 2019, 8, e013485.	1.6	11
59	Effects of cardiac resynchronization therapy in patients unselected for mechanical dyssynchrony. International Journal of Cardiology, 2010, 143, 51-56.	0.8	10
60	Cardioverter-defibrillators: a cost or an investment?. Europace, 2011, 13, ii25-ii31.	0.7	10
61	Greyzone myocardial fibrosis and ventricular arrhythmias in patients with a left ventricular ejection fraction >35%. Europace, 2022, 24, 31-39.	0.7	10
62	Autofluorescence guided welding of heart tissue by laser pulse bursts at 1550 nm. Biomedical Optics Express, 2020, 11, 6271.	1.5	9
63	Is cardiac resynchronisation therapy proarrhythmic?. Indian Pacing and Electrophysiology Journal, 2008, 8, 268-80.	0.3	9
64	Clinical outcomes after upgrading from pacemakers to cardiac resynchronization therapy. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 290-298.	0.5	8
65	Effect of QRS area reduction and myocardial scar on the hemodynamic response to cardiac resynchronization therapy. Heart Rhythm, 2020, 17, 2046-2055.	0.3	8
66	A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RaILRoAD) compared with current standard practice. Trials, 2019, 20, 314.	0.7	6
67	Prognosis of incidental left bundle branch block. Europace, 2020, 22, 956-963.	0.7	6
68	The clinical outcome of cardiac resynchronization therapy in post-surgical valvular cardiomyopathy. Europace, 2016, 18, 732-738.	0.7	5
69	Renal function and the longâ€term clinical outcomes of cardiac resynchronization therapy with or without defibrillation. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 595-602.	0.5	5
70	Clinical outcomes and costs of cardiac revascularisation in England and New York state. Open Heart, 2018, 5, e000704.	0.9	4
71	Inclusion and exclusion criteria for CRT. Heart Rhythm, 2009, 6, 1235-1237.	0.3	3
72	Comparison of magnetic resonance feature tracking for longitudinal strain calculation with spatial modulation of magnetization imaging analysis. Journal of Cardiovascular Magnetic Resonance, 2013, 15, P123.	1.6	3

#	Article	IF	Citations
73	The Role of Cardiovascular Magnetic Resonance in Cardiac Resynchronization Therapy. Cardiac Electrophysiology Clinics, 2015, 7, 619-633.	0.7	3
74	Late perforation of a defibrillator lead managed by percutaneous, intravenous extraction. Europace, 2008, 11, 255-257.	0.7	2
75	Withdrawn as duplicate: Optimized Implementation of cardiac resynchronization therapy â€“ a call for action for referral and optimization of care. Europace, 2023, 25, .	0.7	2
76	New Insights Into the Progression of Aortic Stenosis: Implications for Secondary Prevention. Circulation, 2001, 103, E67.	1.6	1
77	Letter by Taylor et al Regarding Article, â€œMyocardial Fibrosis as a Key Determinant of Left Ventricular Remodeling in Idiopathic Dilated Cardiomyopathy: A Contrast-Enhanced Cardiovascular Magnetic Studyâ€. Circulation: Cardiovascular Imaging, 2013, 6, e78.	1.3	1
78	UK multicenter retrospective comparison of novel active versus conventional passive fixation coronary sinus leads. Journal of Cardiovascular Electrophysiology, 2020, 31, 2948-2953.	0.8	1
79	First-Phase Left Ventricular EjectionÂFraction. JACC: Cardiovascular Imaging, 2021, 14, 2286-2287.	2.3	1
80	The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: insights from an <scp>individual patient data metaâ€analysis</scp> of <scp>COMPANION</scp> and <scp>CAREâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 1091-1093.	2.9	1
81	Patients with Nonischemic Cardiomyopathy Requiring Cardiac Resynchronization Therapy Should Also Undergo Implantation of a Primary Prevention Defibrillator. Cardiac Electrophysiology Clinics, 2015, 7, 461-468.	0.7	0
82	In vitro experimental results using autofluorescence spectroscopy to assess RF ablation of bovine heart. , 2017, , .		0
83	Reply. Journal of the American College of Cardiology, 2021, 77, 2158.	1.2	0
84	Risk Stratification Beyond Left Ventricular Ejection Fraction: Role of Cardiovascular Magnetic Resonance. , 2019, , 11-25.		0
85	Health Economics. , 0, , 419-435.		0
86	Acute Hemodynamic Effects of Simultaneous and Sequential Multi-Point Pacing in Heart Failure Patients With an Expected Higher Rate of Sub-response to Cardiac Resynchronization Therapy: Results of Multicenter SYNSEQ Study. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	0
87	Implantable cardioverterâ€defibrillators for primary prevention of sudden cardiac death: what are the barriers to implementation in the â€˜real worldâ€™?. European Journal of Heart Failure, 2022, 24, 1223-1226.	2.9	0